TR199802693T2 - De�i�tirilmi� 3,5-difenil-1,2,4-triazoller ve eczasal metal kelatorlar olarak kullan�m�. - Google Patents

De�i�tirilmi� 3,5-difenil-1,2,4-triazoller ve eczasal metal kelatorlar olarak kullan�m�.

Info

Publication number
TR199802693T2
TR199802693T2 TR1998/02693T TR9802693T TR199802693T2 TR 199802693 T2 TR199802693 T2 TR 199802693T2 TR 1998/02693 T TR1998/02693 T TR 1998/02693T TR 9802693 T TR9802693 T TR 9802693T TR 199802693 T2 TR199802693 T2 TR 199802693T2
Authority
TR
Turkey
Prior art keywords
triazoles
diphenyl
modified
metal chelators
pharmaceutical metal
Prior art date
Application number
TR1998/02693T
Other languages
English (en)
Turkish (tr)
Inventor
Lattmann Rene
Acklin Pierre
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199802693(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TR199802693T2 publication Critical patent/TR199802693T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TR1998/02693T 1996-06-25 1997-06-24 De�i�tirilmi� 3,5-difenil-1,2,4-triazoller ve eczasal metal kelatorlar olarak kullan�m�. TR199802693T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25

Publications (1)

Publication Number Publication Date
TR199802693T2 true TR199802693T2 (xx) 1999-05-21

Family

ID=4214048

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/02693T TR199802693T2 (xx) 1996-06-25 1997-06-24 De�i�tirilmi� 3,5-difenil-1,2,4-triazoller ve eczasal metal kelatorlar olarak kullan�m�.

Country Status (37)

Country Link
US (3) US6465504B1 (pt)
EP (1) EP0914118B1 (pt)
JP (1) JP3541042B2 (pt)
KR (1) KR100616378B1 (pt)
CN (1) CN1146415C (pt)
AP (1) AP1127A (pt)
AR (1) AR007479A1 (pt)
AT (1) ATE226435T1 (pt)
AU (1) AU718037B2 (pt)
BG (1) BG64248B1 (pt)
BR (1) BR9709973A (pt)
CA (1) CA2255951C (pt)
CY (2) CY2429B1 (pt)
CZ (1) CZ291470B6 (pt)
DE (3) DE122007000020I2 (pt)
DK (1) DK0914118T3 (pt)
ES (1) ES2187785T3 (pt)
FR (1) FR06C0049I2 (pt)
GE (1) GEP20084355B (pt)
HK (1) HK1020530A1 (pt)
HU (1) HU226232B1 (pt)
IL (1) IL127212A0 (pt)
LT (1) LTC0914118I2 (pt)
LU (1) LU91291I2 (pt)
MY (1) MY129541A (pt)
NL (1) NL300248I2 (pt)
NO (3) NO317180B1 (pt)
NZ (1) NZ333308A (pt)
OA (1) OA10946A (pt)
PL (1) PL194758B1 (pt)
PT (1) PT914118E (pt)
RU (1) RU2208010C2 (pt)
SI (1) SI0914118T1 (pt)
SK (1) SK284319B6 (pt)
TR (1) TR199802693T2 (pt)
TW (1) TW533205B (pt)
WO (1) WO1997049395A1 (pt)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
US20090227647A1 (en) 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
CA2547196A1 (en) * 2003-12-19 2005-06-30 Novartis Ag Combination of (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2005115379A2 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
KR101325424B1 (ko) * 2005-01-28 2013-11-04 노파르티스 아게 Ｔｉｅ-2 키나제 활성의 조절에 반응하는 질환의 치료를위한 피리미딜아미노벤즈아미드의 용도
US20080187510A1 (en) * 2005-02-10 2008-08-07 Camenisch Gian P Methods for Improving Drug Disposition
EP1893198A2 (en) * 2005-05-31 2008-03-05 Novartis AG Treatment of liver diseases in which iron plays a role in pathogenesis
WO2007045445A1 (en) * 2005-10-19 2007-04-26 Novartis Ag Dispersible tablets comprising deferasirox
PL1945272T3 (pl) 2005-11-01 2014-03-31 Novartis Ag Sposób prowadzenia scyntygraffi
WO2007128820A1 (en) 2006-05-09 2007-11-15 Novartis Ag Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
WO2008005624A2 (en) * 2006-05-23 2008-01-10 Novartis Ag Method of treatment of hereditary hemochromatosis
TWI448285B (zh) 2006-07-13 2014-08-11 Los Angeles Biomed Res Inst 用以治療白黴菌症（ｍｕｃｏｒｍｙｃｏｓｉｓ）及其他真菌類疾病之組合物及方法
CN101500561A (zh) * 2006-08-04 2009-08-05 诺瓦提斯公司 应用铁螯合剂治疗内分泌功能障碍
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
BRPI0720793A2 (pt) 2006-11-29 2014-03-11 Novartis Ag SAIS E FORMAS CRISTALINAS DE ÁCIDO 4-[3,5-BIS(2-HIDRÓXI FENIL)-[1,2,4]tRIAZOL-1-IL]BENZOICO
US20080262060A1 (en) * 2007-01-29 2008-10-23 Toth Zoltan G Crystalline forms of Deferasirox
MX2009012375A (es) * 2007-05-14 2009-12-01 Novartis Ag Uso de quelante del hierro para el tratamiento del infarto de miocardio.
EP1994930A1 (en) 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
EP2062572A1 (en) 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
CZ301873B6 (cs) * 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
US20110097413A1 (en) * 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
WO2009147529A1 (en) * 2008-06-02 2009-12-10 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
JPWO2010032489A1 (ja) 2008-09-22 2012-02-09 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
US8444985B2 (en) 2009-03-19 2013-05-21 Los Angeles Biomedical Research Institute at Harbor-ULCA Medical Center Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
JP2013512893A (ja) * 2009-12-07 2013-04-18 マピ ファーマ リミテッド デフェラシロクスの調製方法、及びデフェラシロクスの多形体
ES2543427T3 (es) 2010-07-08 2015-08-19 Ratiopharm Gmbh Forma farmacéutica oral de deferasirox
US8907083B2 (en) * 2010-08-25 2014-12-09 Ramamohan Rao Davuluri Process for the preparation, of 2-(2-hydroxyphenyl)-benz [1, 3] oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-IH-I, 2, 4-triazolTI-yl] benzoic acid
MY165826A (en) * 2010-10-01 2018-05-17 Cipla Ltd Pharmaceutical composition
WO2012069946A1 (en) * 2010-11-24 2012-05-31 Alembic Pharmaceuticals Limited Process for the preparation of deferasirox
US9796605B2 (en) 2011-01-14 2017-10-24 Disease Adsorption System Technologies Co., Ltd. Polymeric iron chelating agent
WO2013053927A1 (en) 2011-10-14 2013-04-18 Photocure Asa Photodynamic diagnosis of abnormalities of the epithelial lining of the oesophagus with the means of a 5-ala ester
US20140316534A1 (en) 2011-10-14 2014-10-23 Photocure Asa Stent
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
JP6312718B2 (ja) * 2013-03-06 2018-04-18 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ デフェラシロクスを調製するための方法
LT2964202T (lt) 2013-03-08 2019-02-11 Novartis Ag Deferasirokso peroraliniai preparatai
ZA201403276B (en) * 2013-05-10 2015-07-29 Cipla Ltd Low dose pharmaceutical composition
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
SI3116909T1 (sl) 2014-03-14 2020-03-31 Novartis Ag Molekule protiteles na LAG-3 in njih uporaba
PL2946771T3 (pl) 2014-05-20 2019-10-31 Sanovel Ilac Sanayi Ve Ticaret As Preparat w postaci dyspergowalnej w wodzie tabletki zawierający deferazyroks
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PE20171067A1 (es) 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
JP6878405B2 (ja) 2015-07-29 2021-05-26 ノバルティス アーゲー Ｐｄ−１に対する抗体分子を含む組み合わせ治療
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
WO2017068090A1 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
EP3429562A1 (en) 2016-03-17 2019-01-23 Lupin Limited Compositions of deferasirox
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018059922A1 (en) 2016-09-30 2018-04-05 Synthon B.V. Pharmaceutical composition comprising deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
EP4052698A1 (en) 2021-03-05 2022-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Film coated tablet comprising deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH84663A4 (pt) 1963-01-24 1964-11-14
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
ES2187785T3 (es) 2003-06-16
DE122007000020I2 (de) 2010-12-30
NL300248I2 (nl) 2007-03-01
NO2006017I1 (no) 2006-12-18
LTC0914118I2 (lt) 2018-12-27
LTPA2007001I1 (lt) 2018-06-25
BG64248B1 (bg) 2004-07-30
OA10946A (en) 2003-02-27
WO1997049395A1 (en) 1997-12-31
RU2208010C2 (ru) 2003-07-10
EP0914118A1 (en) 1999-05-12
AP1127A (en) 2002-12-06
NO986024D0 (no) 1998-12-21
CY2429B1 (en) 2004-11-12
DE69716602T2 (de) 2003-06-26
DK0914118T3 (da) 2003-02-24
AU718037B2 (en) 2000-04-06
HUP9903111A2 (hu) 2000-01-28
ATE226435T1 (de) 2002-11-15
SK178598A3 (en) 1999-06-11
CY2007005I1 (el) 2010-07-28
CA2255951A1 (en) 1997-12-31
PL194758B1 (pl) 2007-07-31
HU226232B1 (en) 2008-07-28
GEP20084355B (pt) 2008-04-29
LU91291I9 (pt) 2018-12-27
AR007479A1 (es) 1999-10-27
JP3541042B2 (ja) 2004-07-07
US20030069273A1 (en) 2003-04-10
MY129541A (en) 2007-04-30
DE122007000020I1 (de) 2007-05-24
NL300248I1 (nl) 2007-02-01
NO2018014I1 (no) 2018-04-17
NO2006017I2 (no) 2011-07-04
HK1020530A1 (en) 2000-05-12
KR20050098029A (ko) 2005-10-10
US6596750B2 (en) 2003-07-22
CN1146415C (zh) 2004-04-21
BR9709973A (pt) 1999-08-10
NO317180B1 (no) 2004-09-06
EP0914118B1 (en) 2002-10-23
CN1223579A (zh) 1999-07-21
LU91291I2 (fr) 2007-01-29
NO2018014I2 (no) 2018-11-19
AU3262997A (en) 1998-01-14
SI0914118T1 (en) 2003-04-30
FR06C0049I2 (fr) 2007-04-27
DE69716602D1 (de) 2002-11-28
HUP9903111A3 (en) 2000-06-28
TW533205B (en) 2003-05-21
NO986024L (no) 1998-12-21
US20030203954A1 (en) 2003-10-30
CZ291470B6 (cs) 2003-03-12
CA2255951C (en) 2006-10-10
PT914118E (pt) 2003-02-28
IL127212A0 (en) 1999-09-22
FR06C0049I1 (pt) 2007-03-09
PL330119A1 (en) 1999-04-26
KR100616378B1 (ko) 2006-08-28
CY2007005I2 (el) 2018-12-12
JP2000507601A (ja) 2000-06-20
SK284319B6 (sk) 2005-01-03
CZ427298A3 (cs) 1999-03-17
AP9801407A0 (en) 1998-12-31
BG103003A (en) 1999-09-30
NZ333308A (en) 2000-05-26
US6465504B1 (en) 2002-10-15
US6723742B2 (en) 2004-04-20

Similar Documents

Publication Publication Date Title
TR199802693T2 (xx) De�i�tirilmi� 3,5-difenil-1,2,4-triazoller ve eczasal metal kelatorlar olarak kullan�m�.
TR200000059T2 (tr) Piridin türevleri
BG101112A (en) The use of heterocyclic compounds
NZ332762A (en) Isobutylgaba and its derivatives for the treatment of pain
TR200000009T2 (tr) Triazol bileşikleri ve bunların dopamin-D3-ligandları olarak kullanımları.
HK1033463A1 (en) 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
PL312961A1 (en) Amidine derivatives exhibiting activity of nitrogen oxide synthetase
AU3202595A (en) 1,2-substituted imidazolyl compounds for the treatment of inflammation
PL327735A1 (en) Novel substituted derivatives of imidazole
ATE299890T1 (de) Inhibitoren von gamma-secretase
NZ335981A (en) Ketobenzamides as calpain inhibitors
ZA988158B (en) Sulfinic acid derivatives and their preparation and use
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
MX9604367A (es) Hidroxipiridinonas novedosas.
AU6520098A (en) Azole compounds, their production and their use
NZ513096A (en) Compositions for treating inflammatory response
MY124480A (en) Use of glyceryl triacetate for treating onychomycoses
IL150125A0 (en) Novel compounds
MX9505192A (es) Utilizacion de un antagonista de la substancia p para la obtencion de composiciones farmaceuticas para el tratamiento del enrojecimiento cutaneo de origen neurogenico.
PT775118E (pt) Derivados de benzimidazole com actividade dopaminergica
ATE40822T1 (de) Aromatase-hemmende 1,2,3-triazol-1-yl-, tetrazol- 1-yl- und tetrazol-2-yl-verbindungen.
SI1000034T1 (en) Substituted 6-alkylphenanthridines
NO983283L (no) Hydrokamsyre-baserte Kollagenase-inhibitorer
TR200001926T2 (tr) Vasküler başağrılarına karşı lokal anesteziklerin yeni kullanımı
NO962221D0 (no) Anvendelse av dimeticon for behandling av konstipasjon